JP2010024587A - Antiviral agent and antivirus sheet - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an antiviral agent having excellent safety and easily applicable to the production of products to use the agent. <P>SOLUTION: The antiviral agent contains, as an active component, an anionic surfactant selected from a group consisting of a metal salt of a higher fatty acid of formula R<SP>1</SP>CH<SB>2</SB>COOH (R<SP>1</SP>is a 7-20C aliphatic hydrocarbon group), its sulfonic acid ester or sulfuric acid ester; a metal salt of a sulfuric acid ester of a higher fatty acid ester of formula R<SP>2</SP>COOR<SP>3</SP>(R<SP>2</SP>and R<SP>3</SP>are each a substituted or unsubstituted aliphatic hydrocarbon group; and the total carbon atoms of R<SP>2</SP>and R<SP>3</SP>is 8-21); a metal salt of a sulfuric acid or phosphoric acid ester of a partial ester of a polyhydric alcohol fatty acid of formula R<SP>4</SP>COOCH<SB>2</SB>CH(OH)(CH<SB>2</SB>OH) (R<SP>4</SP>is an 8-21C aliphatic hydrocarbon group); a metal salt of a sulfonic acid of a higher fatty acid ester of formula R<SP>5</SP>COOCH<SB>2</SB>SO<SB>3</SB>H (R<SP>5</SP>is an 8-21C aliphatic hydrocarbon group); and a metal salt of a compound of formula R<SP>6</SP>OCOCH(R<SP>7</SP>OCOCH<SB>2</SB>)SO<SB>3</SB>H (R<SP>6</SP>and R<SP>7</SP>are each an aliphatic hydrocarbon group; and the total carbon atoms of R<SP>6</SP>and R<SP>7</SP>is 8-21). <P>COPYRIGHT: (C)2010,JPO&INPIT

Description

  The present invention relates to an antiviral agent and an antiviral product carrying the antiviral agent, particularly an air filter (used in buildings, vehicles, factories, hospitals, airplanes, etc.), masks, clothing, etc. It is related with the sheet | seat excellent in the activity inhibitory effect of the virus used suitably for the sheet-like article etc. to which a certain influenza virus adheres.

At present, the threat of bird flu is on a global scale and has already landed on mainland Japan. On the other hand, in the living space surrounding the human environment, many types of air filters are used from general buildings where the population is concentrated to large buildings such as hospitals and schools, and homes in the home to improve air quality. However, normal air filters collect microbes such as bacteria, sputum, and viruses as well as dust and harmful gases, but the current situation is that the microbes are scattered along with dust during use or when replacing the filter, and the safety is not sufficient. is there.
Therefore, in order to suppress the activity of microorganisms, filters carrying plant extracts such as silver, copper and catechin, natural minerals, enzymes and the like are used. However, they are expensive because they require special raw materials and manufacturing methods, and are not yet widely used.
In addition, alcohol-based, iodine-based, chlorine-based disinfectants and the like are recommended as general disinfectants such as SARS, but there are concerns about safety when applied to air filters and the like.

  As disclosed in Patent Document 1, it is known that a surfactant is used as a bactericidal effect enhancer for a substance having a specific bactericidal effect against bacteria and sputum. It is not described that the surfactant itself has an inactive action against viruses, and is applied to air filters (used in buildings, vehicles, factories, hospitals, airplanes, etc.), masks, clothing, etc. Is not described.

  Patent Document 2 states that “a fiber having a cross-linked structure and having a carboxyl group in the molecule has an inactivating effect against viruses and is hardly soluble in water and / or a metal compound. "Antiviral fiber characterized in that fine particles are dispersed." However, it is necessary to mix fine particles of metal or metal compound in the resin that constitutes the fiber, and there are restrictions on the fiber type and fiber spinnability, making it difficult to spin fine fibers, There is a problem that the cost increases when the fibers are spun in a small lot. In addition, since only the fiber surface exerts an inactivation effect against viruses, metal fine particles in fibers other than the surface are wasted, and the metal particle utilization efficiency is poor, and fiber physical properties due to metal particles are reduced. There was a problem to do.

  Furthermore, various antiviral agents containing a surfactant as an active ingredient are known. For example, Patent Document 3 discloses a method for inactivating lipid enveloped virus using a nonionic surfactant (for example, Tween), and Patent Document 4 discloses a surfactant that is a protein denaturant (for example, sodium dodecyl sulfate). ) Have been disclosed, respectively.

Special table 2007-520432 gazette International Publication No. 2005/083171 Pamphlet JP-A-10-234362 Japanese Patent Laying-Open No. 2005-095112

Under such circumstances, the present inventor has eagerly searched for an antiviral agent that is excellent in safety and can be easily applied to the production of a product using the same. As a result, a specific anionic surfactant is found. It has been newly found that it has an antiviral action, and further has been found that it can be supported on a fiber sheet by a very simple treatment.
Therefore, the subject of this invention is providing the antiviral agent which is excellent in safety | security and can be applied easily to manufacture of the product using the same.

（式中、Ｒ^２及びＲ^３は、それぞれ、水素原子が水酸基で置換されることのある飽和又は不飽和の脂肪族炭化水素基であり、少なくとも一方が不飽和の脂肪族炭化水素基であり、Ｒ^２の炭素数とＲ^３の炭素数の合計炭素数は８〜２１であり、Ｍは、金属塩を形成することのできる金属である）で表される高級脂肪酸エステルの硫酸エステルの金属塩、
（ｃ）一般式：

（式中、Ｒ^４は、炭素数８〜２１の飽和又は不飽和の脂肪族炭化水素基であり、Ｍは前記と同じ意味である）で表される多価アルコール脂肪酸の部分エステルの硫酸エステルのアルカリ金属塩、又は一般式：

（式中、Ｒ^４及びＭは、前記と同じ意味である）で表される多価アルコール脂肪酸の部分エステルの燐酸エステルのアルカリ金属塩、
（ｄ）一般式Ｒ^５Ｃ（＝Ｏ）ＯＣＨ_２ＳＯ_３Ｍ（式中、Ｒ^５は、炭素数８〜２１の飽和又は不飽和の脂肪族炭化水素基であり、Ｍは、前記と同じ意味である）で表される高級脂肪酸エステルのスルホン酸の金属塩、及び
（ｅ）一般式：

（式中、Ｒ^６及びＲ^７は、それぞれ、飽和又は不飽和の脂肪族炭化水素基であり、Ｒ^６の炭素数とＲ^７の炭素数の合計炭素数は８〜２１であり、Ｍは、前記と同じ意味である）で表される化合物の金属塩、又は一般式：

（式中、Ｒ^８、Ｒ^９、及びＲ^１０は、それぞれ、飽和又は不飽和の脂肪族炭化水素基であり、Ｒ^８の炭素数とＲ^９の炭素数とＲ^１０の炭素数の合計炭素数は１２〜３２であり、Ｍは、前記と同じ意味である）で表される化合物の金属塩
からなる群から選んだ陰イオン界面活性剤を有効成分として含有することを特徴とする、抗ウイルス剤により解決することができる。 Said subject is according to the invention,
(A) A higher fatty acid represented by the general formula R ¹ CH ₂ COOH (wherein R ¹ is a saturated or unsaturated aliphatic hydrocarbon group having 7 to 20 carbon atoms), a sulfonic acid or a sulfate thereof Metal salt,
(B) General formula:

(In the formula, each of R ² and R ³ is a saturated or unsaturated aliphatic hydrocarbon group in which a hydrogen atom may be substituted with a hydroxyl group, and at least one of them is an unsaturated aliphatic hydrocarbon group. The total number of carbon atoms of R ² and R ³ is 8 to 21, and M is a metal capable of forming a metal salt. salt,
(C) General formula:

(Wherein R ⁴ is a saturated or unsaturated aliphatic hydrocarbon group having 8 to 21 carbon atoms, and M has the same meaning as described above) sulfate ester of partial ester of polyhydric alcohol fatty acid represented by Alkali metal salts of the general formula:

(Wherein R ⁴ and M have the same meaning as described above), an alkali metal salt of a phosphate ester of a partial ester of a polyhydric alcohol fatty acid,
(D) General formula R ⁵ C (═O) OCH ₂ SO ₃ M (wherein R ⁵ is a saturated or unsaturated aliphatic hydrocarbon group having 8 to 21 carbon atoms, and M is the same as above) A metal salt of a sulfonic acid of a higher fatty acid ester represented by:

(In the formula, R ⁶ and R ⁷ are each a saturated or unsaturated aliphatic hydrocarbon group, the total number of carbon atoms of R ⁶ and R ⁷ is 8 to 21, and M is , Which has the same meaning as described above), or a general formula:

^(Wherein, R 8, ^{R 9,} and ^{R 10} each is an aliphatic saturated or unsaturated hydrocarbon group, the total carbon number of carbon atoms in the carbon number of the ^{R 10} carbon atoms and ^{R 9} in ^{R 8} An anionic surfactant selected from the group consisting of a metal salt of a compound represented by the formula: It can be solved with a virus agent.

According to a preferred embodiment of the antiviral agent of the present invention, the anionic surfactant is an alkali metal oleate or an alkali metal dioctylsulfosuccinate.
According to another preferred embodiment of the antiviral agent of the present invention, the virus is an influenza virus.

The present invention also relates to an antiviral sheet characterized in that 0.1 to 10% by mass of the anionic surfactant is supported on a breathable sheet.
According to a preferred embodiment of the antiviral sheet of the present invention, the breathable sheet is an air filter medium, a mask substrate, or a medical substrate.

  The anionic surfactant which is an active ingredient of the present invention is excellent in safety and can be easily applied to the production of products using the anionic surfactant. According to the present invention, air filter (used in buildings, vehicles, factories, hospitals, airplanes, etc.), masks, clothing, etc., suitable for sheet-like articles to which influenza viruses that may adversely affect the human body adhere The sheet | seat excellent in the activity suppression effect of the virus used can be provided. In addition, there are no restrictions on the type of breathable sheet and the thickness of the fiber, and various types of sheets and fibers can be applied, and the cost can be kept low.

（式中、Ｒ^２及びＲ^３は、それぞれ、水素原子が水酸基で置換されることのある飽和又は不飽和の分枝状又は直鎖状の脂肪族炭化水素基であり、少なくとも一方が不飽和の分枝状又は直鎖状の脂肪族炭化水素基であり、Ｒ^２の炭素数とＲ^３の炭素数の合計炭素数は８〜２１であり、Ｍは、金属塩を形成することのできる金属である）で表される高級脂肪酸エステルの硫酸エステルの金属塩、
（ｃ）一般式：

（式中、Ｒ^４は、炭素数８〜２１の飽和又は不飽和の分枝状又は直鎖状の脂肪族炭化水素基であり、Ｍは前記と同じ意味である）で表される多価アルコール脂肪酸の部分エステルの硫酸エステルのアルカリ金属塩、又は一般式：

（式中、Ｒ^４及びＭは、前記と同じ意味である）で表される多価アルコール脂肪酸の部分エステルの燐酸エステルのアルカリ金属塩、
（ｄ）一般式Ｒ^５Ｃ（＝Ｏ）ＯＣＨ_２ＳＯ_３Ｍ（式中、Ｒ^５は、炭素数８〜２１の飽和又は不飽和の分枝状又は直鎖状の脂肪族炭化水素基であり、Ｍは前記と同じ意味である）で表される高級脂肪酸エステルのスルホン酸の金属塩、及び
（ｅ）一般式：

（式中、Ｒ^６及びＲ^７は、それぞれ、飽和又は不飽和の分枝状又は直鎖状の脂肪族炭化水素基であり、Ｒ^６の炭素数とＲ^７の炭素数の合計炭素数は８〜２１であり、Ｍは、前記と同じ意味である）で表される化合物の金属塩、又は一般式：

（式中、Ｒ^８、Ｒ^９、及びＲ^１０は、それぞれ、飽和又は不飽和の脂肪族炭化水素基であり、Ｒ^８の炭素数とＲ^９の炭素数とＲ^１０の炭素数の合計炭素数は１２〜３２であり、Ｍは、前記と同じ意味である）で表される化合物の金属塩
からなる群から選んだ陰イオン界面活性剤を使用する。 1. Antiviral agent of the present invention In the antiviral agent of the present invention, as an active ingredient,
(A) a higher class represented by the general formula R ¹ CH ₂ COOH (wherein R ¹ is a saturated or unsaturated branched or linear aliphatic hydrocarbon group having 7 to 20 carbon atoms) Fatty acid, its sulfonic acid or sulfate metal salt,
(B) General formula:

(In the formula, each of R ² and R ³ is a saturated or unsaturated branched or linear aliphatic hydrocarbon group in which a hydrogen atom may be substituted with a hydroxyl group, at least one of which is unsaturated. A branched or straight-chain aliphatic hydrocarbon group, the total number of carbon atoms of R ² and R ³ is 8 to 21, and M can form a metal salt. A metal salt of a sulfate of a higher fatty acid ester represented by
(C) General formula:

(Wherein R ⁴ is a saturated or unsaturated branched or linear aliphatic hydrocarbon group having 8 to 21 carbon atoms, and M has the same meaning as described above). Alkali metal salt of sulfate ester of partial ester of alcohol fatty acid, or general formula:

(Wherein R ⁴ and M have the same meaning as described above), an alkali metal salt of a phosphate ester of a partial ester of a polyhydric alcohol fatty acid,
(D) General formula R ⁵ C (═O) OCH ₂ SO ₃ M (wherein R ⁵ is a saturated or unsaturated branched or linear aliphatic hydrocarbon group having 8 to 21 carbon atoms) And M is the same meaning as described above) and a metal salt of a sulfonic acid of a higher fatty acid ester represented by: (e) a general formula:

(In the formula, each of R ⁶ and R ⁷ is a saturated or unsaturated branched or linear aliphatic hydrocarbon group, and the total number of carbon atoms of R ⁶ and R ⁷ is Or a metal salt of a compound represented by the general formula:

^(Wherein, R 8, ^{R 9,} and ^{R 10} each is an aliphatic saturated or unsaturated hydrocarbon group, the total carbon number of carbon atoms in the carbon number of the ^{R 10} carbon atoms and ^{R 9} in ^{R 8} The number is 12 to 32, and M is the same meaning as described above). An anionic surfactant selected from the group consisting of metal salts of compounds represented by

  In the present specification, the saturated or unsaturated aliphatic hydrocarbon group includes a branched or linear aliphatic hydrocarbon group. The metal salt is not particularly limited as long as it has the antiviral activity of the anionic surfactant, and examples thereof include alkali metal salts (for example, sodium salts and potassium salts). In the present specification, the symbol M used in each general formula representing a metal salt means a metal capable of forming the metal salt unless otherwise specified. Examples of M include alkali metals such as sodium and potassium.

で表される高級脂肪酸のスルホン酸の金属塩、一般式：

［式中、Ｒ^１１及びＲ^１２は、それぞれ、飽和又は不飽和の分枝状又は直鎖状の脂肪族炭化水素基であり、Ｒ^１１の炭素数とＲ^１２の炭素数の合計炭素数は７〜２０（好ましくは１１〜１７）である］で表される高級脂肪酸の硫酸エステルの金属塩が含まれる。 The anionic surfactant (a) includes a metal salt of a higher fatty acid represented by the general formula R ¹ CH ₂ COOM, a general formula:

Metal salts of sulfonic acids of higher fatty acids represented by the general formula:

[Wherein R ¹¹ and R ¹² are each a saturated or unsaturated branched or linear aliphatic hydrocarbon group, and the total number of carbon atoms of R ¹¹ and R ¹² is 7 to 20 (preferably 11 to 17)].

The group R ¹ in the anionic surfactant (a) is a saturated or unsaturated branched or linear aliphatic hydrocarbon group having 7 to 20 carbon atoms (preferably 11 to 17 carbon atoms). As an alkali metal salt of a saturated or unsaturated higher fatty acid, for example, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, palmitoleic acid, oleic acid, linoleic acid, linolenic acid alkali metal Salts, more preferably, alkali metal salts of myristic acid, palmitic acid, stearic acid, oleic acid, and linoleic acid, more preferably alkali metal oleate, particularly potassium oleate preferable.

The groups R ² and R ³ in the anionic surfactant (b) are each an unsubstituted saturated or unsaturated branched or linear aliphatic hydrocarbon group, or one or more hydrogen atoms. (Preferably one) is a saturated or unsaturated branched or linear aliphatic hydrocarbon group substituted with a hydroxyl group, and at least one is unsubstituted or substituted unsaturated branched or straight chain It is a chain-like aliphatic hydrocarbon group, and the total number of carbon atoms of R ² and R ³ is 8 to 21 (preferably 18 to 21). The carbon number of R ² is preferably 7 to 17 (more preferably 15 to 17), and the carbon number of R ³ is preferably 1 to 4. When the anionic surfactant (b) is specifically expressed as an alkali metal salt of an unsaturated higher fatty acid ester sulfate, for example, methyl oleate, butyl oleate, methyl ricinoleate or butyl ricinoleate An alkali metal salt can be mentioned, and a sodium sulfate ester salt is more preferable.

The group R ⁴ in the anionic surfactant (c) is a saturated or unsaturated branched or linear aliphatic hydrocarbon group having 8 to 21 carbon atoms (preferably 12 to 18 carbon atoms). Examples of alkali metal salts of polyhydric alcohol fatty acid partial esters such as sulfuric acid or phosphoric acid esters include alkali metal salts of lauric acid monoglyceryl sulfate, palmitic acid monoglyceryl sulfate, and margaric acid monoglyceryl sulfate. Sulfuric acid ester sodium salt is more preferable.

The group R ⁵ in the anionic surfactant (d) is a saturated or unsaturated branched or linear aliphatic hydrocarbon group having 8 to 21 carbon atoms (preferably 12 to 18 carbon atoms). When expressed as an alkali metal salt of a sulfonic acid of a saturated or unsaturated higher fatty acid ester, for example, capric acid ester, lauric acid ester, myristic acid ester, palmitic acid ester, stearic acid ester, arachidic acid ester, palmitoleic acid ester , Sulfonic acid alkali metal salts of higher fatty acid esters such as oleic acid ester, linoleic acid ester, and linolenic acid ester, and more preferably, myristic acid ester, palmitic acid ester, stearic acid ester, oleic acid ester, Sulfo of higher fatty acid esters such as linoleic acid esters Examples thereof include alkali metal salts of acid, and sodium sulfonate is more preferable.

で表されるスルホトリカルバリル酸トリヘキシルエステルのナトリウム塩も適用可能である。式中、Ｒ^８、Ｒ^９、及びＲ^１０は、それぞれ、飽和又は不飽和の分枝状又は直鎖状の脂肪族炭化水素基であり、Ｒ^８の炭素数とＲ^９の炭素数とＲ^１０の炭素数の合計炭素数は１２〜３２（好ましくは１５〜３０）である。Ｒ^８、Ｒ^９、Ｒ^１０の各炭素数は、好ましくは５〜８である。 The groups R ⁶ and R ⁷ in the anionic surfactant (e) are each a saturated or unsaturated branched or linear aliphatic hydrocarbon group, and the number of carbons of R ^{6 and} the number of R ⁷ The total number of carbon atoms is 8 to 21 (preferably 10 to 20). R ⁶ preferably has 5 to 8 carbon atoms, and R ⁷ has preferably 5 to 8 carbon atoms. When the anionic surfactant (e) is specifically expressed as an alkali metal salt of sulfosuccinic acid, for example, an alkali metal salt of dibutyl sulfosuccinic acid, diamyl sulfosuccinic acid, dihexyl sulfosuccinic acid, dioctyl sulfosuccinic acid can be mentioned, The alkali metal salt of dioctylsulfosuccinic acid is more preferable, and the sodium salt of dioctylsulfosuccinic acid is particularly preferable.
In addition, a general formula having a structure similar to an alkali metal salt of sulfosuccinic acid:

A sodium salt of sulfotricarballylic acid trihexyl ester represented by the formula is also applicable. In the formula, each of R ⁸ , R ⁹ , and R ¹⁰ is a saturated or unsaturated branched or linear aliphatic hydrocarbon group, and the carbon number of R ⁸ , the carbon number of R ⁹ , and R The total number of carbon atoms of ¹⁰ is 12 to 32 (preferably 15 to 30). Each carbon number of R ⁸ , R ⁹ , R ¹⁰ is preferably 5-8.

In the antiviral agent of the present invention, at least one of the anionic surfactants (a) to (e) can be used alone or in combination as an active ingredient.
The content of the active ingredient varies depending on the type and application method of the virus. For example, a suitable amount is appropriately determined by conducting a preliminary test based on the contact test method described in Examples described later. Can do.

  The antiviral agent of the present invention can be used in various forms. For example, the antiviral agent can be used by supporting it on a product that may come into contact with a virus. Examples of products that can carry the antiviral agent of the present invention include breathable sheets, medical instruments, interior materials such as wall materials, and clothes.

  Viruses to which the antiviral agent of the present invention can be applied include viruses having envelopes in virus particles, such as influenza viruses derived from hosts such as birds, humans, pigs, horses, SARS coronaviruses, Japanese encephalitis viruses, Ebola viruses , Rabies virus, measles virus, human immunodeficiency virus and the like.

2. Antiviral sheet of the present invention The breathable sheet used in the present invention is not particularly limited as long as it has breathability, and for example, a nonwoven fabric, a woven or knitted fabric, a porous film, and the like are applicable.

As the non-woven fabric, for example, a binder-bonded non-woven fabric, a hydroentangled non-woven fabric, a needle punched non-woven fabric, a fiber-bonded non-woven fabric, a spunbonded non-woven fabric, or a non-woven fabric in which paper is appropriately combined can be applied. Moreover, it is preferable that the fiber diameter of the said melt blown nonwoven fabric is 10 micrometers or less.
The material of the nonwoven fabric is not particularly limited, and polyester fibers such as polyethylene terephthalate and polybutylene terephthalate, polyamide fibers such as nylon 6 and nylon 66, polyolefin fibers such as polypropylene and polyethylene, and acrylic fibers such as polyacrylonitrile. , Not only synthetic fibers such as polyvinyl alcohol fiber and synthetic pulp, but also semi-synthetic fibers such as rayon, natural fibers such as cotton and pulp fibers, or glass fibers, ceramic fibers, metal fibers, etc. can do.

The antiviral sheet of the present invention comprises the anionic surfactants (a) to (e) in an amount of 0.1 to 10% by mass, preferably 0.3 to 10% by mass, based on the mass of the breathable sheet. More preferably, it is carried in an amount of 0.5 to 7 mass%, more preferably 0.7 to 3 mass%. If the amount is less than these ranges, the anionic surfactant may not uniformly adhere to the breathable sheet.If the amount is more than these ranges, the breathability may be reduced or the wettability may be excessive, causing stickiness. May occur.
The method for supporting the breathable sheet method is not particularly limited, but for example, an aqueous solution of an anionic surfactant is prepared, and the aqueous solution is applied and sprayed to the breathable sheet, or After being immersed in the aqueous solution, the antiviral sheet of the present invention can be produced by drying.

  EXAMPLES Hereinafter, the present invention will be specifically described by way of examples, but these do not limit the scope of the present invention.

Example 1: Preparation of antiviral air filter
In this example, 15% by mass of polypropylene fiber having an average fiber diameter of 3 μm formed by a melt blow method and a core-sheath type composite fiber having an average fiber diameter of 30 μm as a heat-adhesive fiber (the core resin component is polypropylene resin, The air filter medium of the present invention was prepared using a medium-high performance air filter medium in which 85% by mass of the resin component of the sheath (polyethylene resin) is mixed and the constituent fibers are bonded with the heat-adhesive fibers. . The air filter medium before chemical treatment had a mass of 130 g / m ² , a thickness of 1.2 mm, and a pressure loss of 120 Pa (when the passing wind speed was 10 cm / s).

As the agent for the air filter medium of the present invention, sodium dioctylsulfosuccinate [ROCOCH (ROCOCH ₂ ) SO ₃ Na; R has 7 carbon atoms] and potassium oleate (RCOOK; R has 17 carbon atoms) were used. . As the drug for an air filter medium for comparison, sodium alkanesulfonate _[RSO 3 Na; number of carbon atoms in R is 14 to 18] were used.
The air filter medium was immersed in an aqueous solution containing each drug (drug concentration = 0.3%) for 1 minute, then squeezed with a mangle roll, and dried by hot air heating (120 ° C.). The amount of drug attached was 1% by mass with respect to the filter medium.

<< Example 2: Virus contact test >>
The test virus is avian influenza [A / whistling swan / Shimane / 499/83 (H5N3)
]It was used.
The virus was diluted to 2.0 × 10 ⁷ EID ₅₀ /0.1 mL with sterile phosphate buffered saline (PBS) to prepare a virus solution. 0.5 mL of the virus solution was placed on a test filter medium (5 cm × 5 cm) in a plastic petri dish and covered with a plastic bag for stomacher (4 cm × 4 cm). It was left still for 10 minutes at room temperature in a dark place, and the virus was brought into contact with the test filter medium. Virus was washed out of the test filter medium using 10 mL of PBS supplemented with antibiotics. The obtained virus washing solution was serially diluted 10-fold with antibiotics-added PBS, and then 0.1 mL was inoculated into the chorioallantoic cavity of 10-day-old chicken eggs. After the embryonated chicken eggs are cultured at 37 ° C. for 2 days, the presence or absence of virus growth in the chorioallantoic cavity is confirmed by the hemagglutination (HA) test, and it is inactive even in contact with the test filter medium in the virus washing solution. The virus infection titer (virus titer) that was not converted was calculated by the Reed-Muench method.

The results of the sodium dioctyl sulfosuccinate (hereinafter referred to as “drug A”)-carrying filter medium and the potassium oleate (drug B) -carrying filter medium of the present invention are shown in Table 1 and Table 2, respectively. ) The results of the supported filter media are shown in Table 3, and the results of the negative control untreated filter media are shown in Table 4, respectively. In Table 1 to Table 4, each numerical value of the dilution ratio column indicates the power value of the dilution factor, for example, "- 3" indicates that the virus washout was 10 ³ dilution. Symbols a to c indicate the results of three different eggs, “+” indicates that the virus has grown (positive), and “−” indicates that the virus has not grown (negative).

From the test results in Tables 1 to 4, the infectivity value (log ₁₀ EID ₅₀ /0.1 mL) of each test filter medium is expressed by the following formula (1):
[Infectious titer] =-A-{(B-50) / (B-C)} (1)
[In the formula, A is the dilution rate at which the cumulative positive rate exceeds 50%, B is the cumulative positive rate at A, and C is the initial normal positive rate at the dilution rate at which the cumulative positive rate is below 50%. is there]
The results are shown in Table 5.

  As shown in Table 5, in the filter medium of the present invention carrying the drug A (sodium dioctylsulfosuccinate) or the drug B (potassium oleate), a virus suppressing effect was observed, but the drug C (alkanesulfonic acid) for comparison was used. In the filter medium carrying sodium), no virus suppression effect was observed.

<< Example 3: Virus contact test of dust-loaded filter medium >>
In this example, for the purpose of investigating the influence of the air filter on the virus suppression effect by collecting the dust during use, the room air was continuously passed through the test air filter medium carrying the medicine A (wind speed). 50 cm / s), and airborne dust was collected. Ventilation was completed in 2 months or 4 months, and the same virus contact test as in Example 2 was performed.
The results are shown in Table 6.

  The antiviral sheet of the present invention can be used, for example, as an air filter medium, a mask substrate, or a medical substrate. Examples of the air filter medium include a prefilter medium, a medium / high performance filter medium, a HEPA / ULPA filter medium, a gas adsorption filter medium, and an antibacterial antifungal filter medium. A filter medium in which an air filter medium and an electret filter are combined is also possible.

Claims (5)

(A) A higher fatty acid represented by the general formula R ¹ CH ₂ COOH (wherein R ¹ is a saturated or unsaturated aliphatic hydrocarbon group having 7 to 20 carbon atoms), a sulfonic acid or a sulfate thereof Metal salt,
(B) General formula:

(In the formula, each of R ² and R ³ is a saturated or unsaturated aliphatic hydrocarbon group in which a hydrogen atom may be substituted with a hydroxyl group, and at least one of them is an unsaturated aliphatic hydrocarbon group. The total number of carbon atoms of R ² and R ³ is 8 to 21, and M is a metal capable of forming a metal salt. salt,
(C) General formula:

(Wherein R ⁴ is a saturated or unsaturated aliphatic hydrocarbon group having 8 to 21 carbon atoms, and M has the same meaning as described above) sulfate ester of partial ester of polyhydric alcohol fatty acid represented by Alkali metal salts of the general formula:

(Wherein R ⁴ and M have the same meaning as described above), an alkali metal salt of a phosphate ester of a partial ester of a polyhydric alcohol fatty acid,
(D) General formula R ⁵ C (═O) OCH ₂ SO ₃ M (wherein R ⁵ is a saturated or unsaturated aliphatic hydrocarbon group having 8 to 21 carbon atoms, and M is the same as above) A metal salt of a sulfonic acid of a higher fatty acid ester represented by:

(In the formula, R ⁶ and R ⁷ are each a saturated or unsaturated aliphatic hydrocarbon group, the total number of carbon atoms of R ⁶ and R ⁷ is 8 to 21, and M is , Which has the same meaning as described above), or a general formula:

^(Wherein, R 8, ^{R 9,} and ^{R 10} each is an aliphatic saturated or unsaturated hydrocarbon group, the total carbon number of carbon atoms in the carbon number of the ^{R 10} carbon atoms and ^{R 9} in ^{R 8} An anionic surfactant selected from the group consisting of a metal salt of a compound represented by the formula: Viral agent.   The antiviral agent according to claim 1, wherein the anionic surfactant is an alkali metal oleate or an alkali metal dioctylsulfosuccinate.   The antiviral agent according to claim 1 or 2, wherein the virus is an influenza virus.   An antiviral sheet comprising 0.1 to 10% by mass of the anionic surfactant according to claim 1 supported on a breathable sheet.   The antiviral sheet according to claim 4, wherein the breathable sheet is an air filter medium, a mask base material, or a medical base material.